PRENW • NASDAQ
Prenetics
$0.0098
개장 전 거래:
$0.010
(2.04%)+0.00020
마감됨:1월 31일, 오후 8시 0분 0초 GMT-5 · USD · NASDAQ · 면책조항
미국 상장 증권
전일 종가
$0.0083
52주 변동폭
$0.0042 - $0.021
시가총액
6414.04만 USD
평균 거래량
2.85만
시장 뉴스
재무
손익계산서
수익
순이익
(USD)2024년 9월전년대비 변동
수익
777.80만59.86%
운영비
1575.58만2.99%
순이익
-1067.22만21.36%
순이익률
-137.2150.80%
주당 수익
EBITDA
-1070.63만14.43%
유효 세율
0.62%
총자산
총부채
(USD)2024년 9월전년대비 변동
현금 및 단기 투자
4868.96만-45.29%
총자산
2.36억-14.71%
총부채
5567.04만16.88%
총자기자본
1.80억
발행 주식
1272.28만
주가순자산비율
0.00
총자산이익률
-12.59%
자본이익률
-15.54%
순현금흐름
(USD)2024년 9월전년대비 변동
순이익
-1067.22만21.36%
영업 현금 흐름
투자 현금 흐름
자금 조달 현금 흐름
순현금흐름
잉여 현금 흐름
정보
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
설립
2014
웹사이트
직원 수
322
검색
검색어 지우기
검색 닫기
Google 앱
기본 메뉴